Short Interest in Clearmind Medicine Inc. (NASDAQ:CMND) Drops By 80.3%

Clearmind Medicine Inc. (NASDAQ:CMND) was the target of a significant decrease in short interest during the month of May. As of May 29th, there was short interest totaling 40,505 shares, a decrease of 80.3% from the May 14th total of 205,330 shares. Currently, 4.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 5,667,197 shares, the short-interest ratio is presently 0.0 days.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of Clearmind Medicine to a “sell” rating in a report on Saturday, May 23rd.

Clearmind Medicine Price Performance

NASDAQ:CMND opened at $3.39 on Wednesday. The firm has a market capitalization of $3.46 million, a price-to-earnings ratio of -0.02 and a beta of 0.64. The company’s 50-day moving average is $6.65 and its two-hundred day moving average is $18.04. Clearmind Medicine has a 1-year low of $2.10 and a 1-year high of $524.00.

Clearmind Medicine (NASDAQ:CMND) last posted its earnings results on Thursday, March 12th. The company reported ($33.20) earnings per share for the quarter.

Clearmind Medicine Company Profile

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.